Introduction
Laboratory mouse strains have been classi®ed into sensitive, intermediate and resistant groups in terms of susceptibility to urethane-induced lung carcinogenesis. The A/J mouse strain belongs to the sensitive group with at least a 20 times higher susceptibility than resistant strains like C3H/HeJ (C3H) and C57BL/6J (B6) (Malkinson and Beer, 1983) . The dierence is largely determined by the Pas1 (Pulmonary adenoma susceptibility 1) locus on chromosome 6, the sensitive A/J allele of which is phenotypically dominant in the F 1 progeny between A/J and C3H or B6 (Gariboldi et al., 1993; Devereux et al., 1994; Festing et al., 1994; Dragani et al., 1995) .
The BALB/cByJ (BALB) strain is 15 times less susceptible than the A/J strain with regard to lung carcinogenesis and is thus considered a member of the intermediate group (Malkinson and Beer, 1983) . In (A/ J6BALB)F 1 mice, the relatively resistant BALB phenotype, unlike the full resistance of C3H and B6, is dominant over the high sensitivity of A/J, indicating the existence of a dominant lung tumor resistance gene that can partially suppress expression of the A/J phenotype (Malkinson and Beer, 1983) . In fact, we recently identi®ed a single major resistance gene on chromosome 18 of BALB mice, designated Par2 (Pulmonary adenoma resistance 2), by analysing (A/J6BALB)F 1 6A/J backcross animals (Obata et al., 1996) .
The Pas1 locus on chromosome 6 is tightly linked to the Kras2 proto-oncogene locus. Activating point mutations of the Kras2 gene are commonly seen in both mouse (Belinsky et al., 1989; You et al., 1989) and human (Suzuki et al., 1990) lung tumors. In fact, a series of studies by You and his coworkers has provided evidence that the two genes, Pas1 and Kras2 could be identical. They ®rst reported that, in lung tumors developing in F 1 mice from A/J and C3H crosses, the A/J allele of the Kras2 was preferentially activated (You et al., 1992) . Subsequently, they demonstrated the A/J Kras2 allele to be more abundantly expressed than the C3H allele in the F 1 lung tumors, the dierence being apparently due to sequential polymorphism in the second intron of the gene (Chen et al., 1994) . The A/J and C3H alleles were designated K s and K r , respectively, and characterization of many laboratory mouse strains for the Kras2 polymorphism revealed that most resistant strains, including B6, carry the K r allele. On the other hand, strains with the K s allele are highly or intermediately susceptible to lung carcinogenesis. These ®ndings indicate that the Kras2 oncogene is a good candidate for the Pas1 gene. However, it should be also noted that this hypothesis still lacks direct proof (Fijneman et al., 1994; Manenti et al., 1995) .
The intermediately sensitive BALB strain was originally derived from Bagg albino random-bred animals, while the A/J strain is the result of a cross between the Bagg and Cold Spring Harbor stocks, so that they are genetically related. Interestingly, BALB mice have the same susceptible K s allele of Kras2 as A/J mice (Chen et al., 1994) . Recently, Massey et al. (1995) reported that the BALB/cJ alleles were preferentially activated in lung tumors of (B66BALB/cJ)F 1 mice carrying activating point mutations within codon 12 of the Kras2 (Massey et al., 1995) . It is thus tempting to assume that, in BALB mice, the phenotypic expression of the sensitive Pas1 allele is suppressed by the dominantly resistant Par2 locus on chromosome 18, resulting in their intermediate phenotype.
To test this hypothesis, we investigated the phenotypic eects of the two established quantitative trait loci, Pas1 and Par2, in (C3H6BALB)F 1 6C3H backcross mice. We thereby found that the presence of the BALB Pas1 allele is linked to sensitivity to urethane lung carcinogenesis. Negative modulation of the BALB Pas1 phenotype by the BALB Par2 gene was also found. In addition, we observed that, in the backcross population, activating point mutations of the Kras2 codon 61 occurred exclusively in the tumors of the BALB Pas1-positive mice and limited to the BALB Kras2 allele.
Results
Development of lung tumors in BALB, C3H and (C3H6BALB)F 1 mice treated with urethane Ten BALB, 10 C3H and 14 (C3H6BALB)F 1 male mice were examined and found to have mean tumor multiplicities of 2.0+1.3, 0.1+0.3 and 2.1+1.4 (Mean+s.d.), respectively. As expected, the C3H value was signi®cantly lower than those for the BALB or (C3H6BALB)F 1 cases (P50.01), while there was no signi®cant dierence between those latter, indicating that the BALB phenotype is dominant.
Phenotypic eects of the BALB Pas1 gene in (C3H6BALB)F 1 6C3H backcross mice
The backcross mice were genotyped at the Kras2 locus on distal chromosome 6, tightly linked to the Pas1 locus, and the proximal D6Mit261 locus. Mice heterozygous at the Kras2 locus showed a mean tumor multiplicity of 2.4, which is signi®cantly higher than the value of 0.3 for homozygotes (P50.000001) ( Table 1 ), indicating that the BALB Pas1 allele is dominantly sensitive over the C3H allele. LOD score analysis gave values of 22.6 for the Kras2 locus and 4.9 for the D6Mit261 locus (Table 1) . The Kras2 locus could explain 48% of the phenotypic variance in the backcross population.
Phenotypic eects of the BALB Par2 gene in (C3H6BALB)F 1 6C3H backcross mice
The Par2 locus is known to be tightly linked to the D18Mit142 locus on distal chromosome 18 (Obata et al., 1996) . Thus, the backcross mice were genotyped at this locus and its¯anking marker loci, D18Mit152 and D18Mit49. When we simply classi®ed the backcross mice into D18Mit142 heterozygote and homozygote groups, the mean tumor multiplicities were not signi®cantly dierent between the two. Since the Par2 gene was originally identi®ed in (A/J6BALB)F 1 6A/J backcross mice, all of which carry the Pas1 disease allele, the phenotypic eect of the BALB Par2 could be Pas1-dependent. Thus, we ®rst classi®ed the (C3H6BALB)F 1 6C3H backcross mice into Kras2 heterozygotes and homozygotes and then subclassi®ed them according to the chromosome 18 genotype. In the backcross population with BALB Kras2, the presence of the BALB allele at the D18Mit142 locus resulted in a signi®cant decrease in the mean tumor multiplicity (P=0.00005, LOD=4.4; Table 2 ). The D18Mit142 locus could explain 20% of the phenotypic variance in the backcross population heterozygous for Kras2. However, this negative eect was not evident in the other population homozygous for the C3H Kras2 allele ( Table 2) .
Eects of the Pas1 and Par2 genes on tumor size
To investigate the eects of the Pas1 and Par2 loci on tumor size, the backcross mice were classi®ed according to the genotypes at the Kras2 and D18Mit142 loci. For Kras2 homozygotes, the data for D18Mit142 homozygotes and heterozygotes were combined, because only a limited number of tumors were produced and the D18Mit142 genotype did not aect the tumor load. We found tumors developing in the Kras2 heterozygotes to be signi®cantly larger in diameter than those in the homozygotes, irrespective of the D18Mit142 genotype (0.77+0.32 mm (mean+s.d.) for the Kras2 heterozygotes and 0.48+0.30 mm for the homozygotes, P50.000001; Figure 1 ). On the other hand, no eect of the D18Mit142 genotype on tumor size was apparent in the Kras2 heterozygotes (0.81+0.33 mm for the D18Mit142 heterozygotes and 0.75+0.32 mm for the homozygotes; Figure 1) . Thus, the Pas1 gene, but not Par2 gene, in¯uenced the lung tumor size.
Analysis of codon 61 point mutations of Kras2 in lung tumors of (C3H6BALB)F 1 mice
In the vast majority of Kras2-activated mouse lung tumors induced by urethane or its metabolite, vinyl carbamate, the activation is speci®cally caused by an A to G transition or an A to T transversion at the second position of codon 61 (You et al., 1989 (You et al., , 1992 Re et al., 1992; Ohmori et al., 1992) . Since these point mutations create a novel TaqI or XbaI restriction site, respectively (George et al., 1985) , we analysed their allelic preference in lung tumors of (C3H6BALB)F 1 mice using a polymerase chain reaction (PCR)-based, nonisotopic restriction fragment length polymorphism (RFLP) method (Lee and Drinkwater, 1995a) . Locations of the PCR primers used for the Kras2 mutation analysis are shown in Figure 2 and the expected fragment sizes of TaqI or XbaI-digested PCR products of the wild or mutant Kras2 alleles ampli®ed by KrasF and KrasR2 primers are indicated in Table 3 . Eleven tumors taken from dierent animals were analysed.
When multiple tumors were observed in an animal, the largest one was chosen. We ampli®ed the tumor DNAs with KrasF and KrasR2 primers and found that all contained the TaqI polymorphism within the Kras2 codon 61 (Figure 3a) , indicating activation by the A to G transition. We next analysed ScaI RLFP of Kras2 intron 3 sequence ampli®ed with KrasF and KrasR PCR primers to explore the parental bias for the codon 61 mutations (Figure 3b ). The BALB intron 3 was resistant to ScaI digestion, while the C3H intron 3 was sensitive. We also con®rmed that the A/J Kras2 allele is the same as the BALB allele in terms of the ScaI polymorphism (data not shown). To determine which allele was mutated in (C3H6BALB)F 1 mouse tumors, their genomic DNAs were ampli®ed by PCR with the KrasF and KrasR primers, digested with ScaI and run on agarose gels. The C3H and BALB products were separately extracted for each tumor and used as templates for PCR with KrasF and KrasR2 primers. Each C3H or BALB PCR product was examined for the TaqI RFLP to detect the A to G transition at the second position of Kras2 codon 61. As illustrated in Figure 3c , the BALB allele was selectively mutated in all 11 cases.
Eects of the Pas1 and Par2 genes on the Kras2 codon 61 mutation frequency in the (C3H6BALB)F 1 6C3H backcross mice
Since the Kras2 codon 61 mutations were frequently observed in the tumors of (C3H6BALB)F 1 mice and this oncogene has been considered a candidate for the Pas1 gene, we analysed the eects of allelic dierences in Kras2 or Pas1, and Par2 on the Kras2 codon 61 mutation frequency. Only one tumor largest in size was collected from each backcross mouse, because our aim was to elucidate whether the Kras2 mutations confer growth advantage. As shown in Table 4 , 25 out of 40 (Lander and Botstein, 1989 ). e Kras2 is tightly linked to Pas1 (Lander and Botstein, 1989 ). The BALB and A/J allele of Kras2 has a ScaI site in intron 3, but the C3H allele does not tumors, taken from dierent BALB Kras2-positive backcross mice, contained the TaqI or XbaI RFLP, in contrast to none of 17 tumors from the negative mice. A very small percentage of urethane-induced mouse lung tumors were reported to carry an A to T or an A to C conversion at the third position of Kras2 codon 61 (Re et al., 1992; Ohmori et al., 1992) . Since these point mutations create a novel RcaI or MaeIII restriction site, respectively, we also analysed the tumor-derived PCR products for RcaI and MaeIII RFLPs. Only one tumor from a backcross mouse heterozygous for both Kras2 and D18Mit142 was found to be positive for the RcaI RFLP (Table 4) . Furthermore, all tumors were examined for point mutations within codon 12 (see Materials and methods) and only one of them heterozygous for both Kras2 and D18Mit142 was positive (Table 4) . Finally, 68% of tumors from BALB Kras2-positive backcross mice, but none from the negative mice, contained Kras2 mutations (Table 4 ). This dierence was statistically signi®cant (P=0.000002). The D18Mit142 (i.e. Par2) genotype did not signi®cantly aect the Kras2 mutation frequency (Table 4) .
We also con®rmed that Kras2 mutations detected by the TaqI RFLP exclusively occurred in the BALB allele of the backcross mice heterozygous for Kras2 (Table  4) .
Discussion
Malkinson and Beer ®rst recognized the uniqueness of the intermediate sensitivity of BALB mice to urethaneinduced lung carcinogenesis (Malkinson and Beer, 1983) . While the sensitive phenotype of the A/J strain was expressed in F 1 crosses with the resistant B6 or C3H strain, the intermediate phenotype of BALB was observed in crosses between A/J and BALB. They also suggested that the dominant resistance of BALB relative to A/J derives from an allelic dierence in a single genetic locus (Malkinson and Beer, 1983) . In our previous study, we attempted to identify the BALB resistance gene by linkage analysis of (A/ J6BALB)F 1 6A/J backcross mice and found the gene designated Par2 located on distal chromosome 18 (Obata et al., 1996) . Linkage analyses from three independent laboratories using segregating crosses between A/J, and C3H or B6 did not detect any phenotypic eect of the Par2 locus (Gariboldi et al., 1993; Devereux et al., 1994; Festing et al., 1994) , indicating that the BALB allele of Par2 has a unique biological activity. However, the fact that BALB mice with the dominant resistance gene, Par2, are phenotypically intermediate, but not resistant, remained a puzzle (Obata et al., 1996) .
The Pas1 gene on chromosome 6, which is the major genetic determinant of the sensitive phenotype of A/J mice, has a large dominant phenotypic eect with almost complete penetrance and thus can be considered an autosomally inherited dominant disease gene for lung cancer. Indeed, this strain also shows an abnormally high incidence of spontaneous lung tumors (Strong, 1936; Bittner, 1938) . In the present study, we demonstrated that the BALB mouse possesses the disease allele of the Pas1, despite its relative resistance to lung carcinogenesis, but that its expression is apparently hidden by the presence of the dominant disease resistance gene, Par2. This explanation resolves the paradox mentioned above. We Lee and Drinkwater, 1995b) . The two-stage concept of carcinogenesis is applicable to the mouse lung. In the ®rst stage, initiation, cells are converted to a preneoplastic status due to mutational events. In the second stage, the preneoplastic or initiated cells are stimulated to grow and form focal lesions. Therefore, sensitivities to initiation and promotion can be evaluated by number and size of the altered lesions, respectively. Schematically, the Pas1 can be considered to aect both initiation and promotion, because the BALB allele was found to be associated with signi®cant increase in tumor number as well as size. However, it must be pointed out that, under our conditions, focally proliferative lesions smaller than 0.1 mm in diameter are not detectable. The numbers of lesions are therefore de®nitely underestimated. In consideration of this bias, the eect of Pas1 on initiation must be considered equivocal, although it is clear that the gene does aect the promotion stage. On the other hand, the BALB allele of Par2 reduced only the number of the lesions, but not their size distribution, suggesting that it primarily in¯uences the earliest stage of carcinogenesis. Interestingly, Dragani et al. observed lung tumor size to be similar in urethane-treated A/J and BALB mice despite a dierence in tumor multiplicity, whereas the lung tumors developing in C3H mice were much smaller than in the A/J case (Dragani et al., 1991a) . This result also provides support for the idea that the BALBunique Par2 gene is involved in initiation or an early stage of tumor development.
The Kras2 gene has been regarded as a candidate for the Pas1 gene (Malkinson and You, 1994) , although there is still a controversy regarding this issue (Fijneman et al., 1994; Manenti et al., 1995) . The primary evidence for this hypothesis is that the Kras2 is tightly linked to the Pas1 on chromosome 6 and that the A/J Kras2 allele is preferentially activated by point mutation in lung tumors developing in F 1 mice from A/ J and C3H crosses (You et al., 1992) . Furthermore, the Kras2 intron 2 of resistant mouse strains, including C3H and B6, contains a tandem repeat of a 37 bp sequence which the sensitive strains represented by A/J and SWR/J lack (Chen et al., 1994) . Malkinson and You hypothesized that this intron 2 polymorphism could be the direct cause for the selective activation of the A/J Kras2 allele in the F 1 mouse tumors (Malkinson and You, 1994) . Inconsistent with this idea, Manenti et al. recently reported that tumors from (A/J6Mus spretus)F 1 mice had the Kras2 mutation again in only the A/J allele despite the absence of the 37 bp tandem repeat in the Mus spretus intron 2, although this does not necessarily preclude Kras2 being the Pas1 gene .
According to the polymorphism in the Kras2 intron 2, the BALB strain should be classi®ed into the sensitive group like the A/J strain (Chen et al., 1994) . Massey et al. (1995) were the ®rst to demonstrate that activating point mutations of the Kras2 also occurred preferentially in the BALB/cJ allele of lung tumors developing in (B66BALB/cJ)F 1 mice. Because of the spontaneous nature of the tumors they analysed, they found the Kras2 mutations at both codon 12 and 61. Using the polymorphism in the intron 2, they showed that the codon 12 mutations were located almost exclusively in the BALB/cJ allele. In this study, we found that the BALB allele is also the same as the A/J allele concerning the ScaI restriction length polymorphism in the intron 3 . By virture of this polymorphism, we con®rmed that the BALB Kras2 is selectively activated in the urethaneinduced tumors in (BALB6C3H)F 1 mice by a carcinogen-speci®c A to G transition at the second position of codon 61.
The fact that many of the urethane-induced lung tumors from the backcross mice also contained Kras2 codon 61 mutations limited to the BALB allele is intriguing. This suggests that activating point mutations within the codon 61 of BALB Kras2 may confer a growth advantage on urethane-initiated lesions. Although the Hras1 mutation frequency of mouse liver tumors has been reported to positively correlate with genetic susceptibility to hepatocarcinogenesis (Dragani et al., 1991b; Buchmann et al., 1991) , this is not necessarily the case for Kras2 in lung carcinogenesis. For example, it has been shown that almost all dimethylnitrosamine (DMN) or 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumors developing in C3H as well as A/J mice possess an activated Kras2 with a speci®c G to A transition at the second position of codon 12 (Belinsky et al., 1989; Devereux et al., 1991; Chen et al., 1993; Matzinger et al., 1994 ). This appears to be in contradiction with our data. However, Devereux et al. (1991) noted that DMN or NNK-induced tumors in A/J mice proliferated more rapidly than those in C3H mice. Since our experiments were terminated within a relatively short period (i.e. 120 days after urethane application), it is conceivable that Kras2-mutated lesions in BALB Kras2-negative backcross mice could not reach a detectable size. It is also noteworthy that the mutation frequency of the Kras2-heterozygous backcross mice (68%) was signi®cantly lower than that of (B66BALB/cJ)F 1 mice (100%). Thus, other genes may aect the mutation frequency in Kras2. We excluded the possibility that Par2 might be one such gene.
Recent studies on genetic control of murine susceptibility to chemical carcinogenesis have revealed that this is often determined by polygenes, each with only a small phenotypic eect or even no eect due to an epistatic nature (Fijneman et al., 1996; van Wezel et al., 1996) . This complexity inevitably makes both molecular and biological analyses of the involved genes extremely dicult. In this regard, the lung carcinogenesis model has a de®nite advantage because of the highly penetrant susceptibility gene, Pas1. In BALB mice, the sensitive Pas1 phenotype is modulated by a single major gene, Par2, so that they provide a useful model for analysing the interactions between tumor susceptibility and resistance genes. Another lung tumor resistance gene of Mus spretus mice, Par1 (Pulmonary adenoma resistance 1), which modulates the Pas1 phenotype was also identi®ed by Manenti et al. (1996) . Molecular identi®cation of these murine genes and their functional analysis should aid fundamental understanding of tumor pathogenesis and its prevention in man.
Materials and methods

Animals
BALB and C3H mice were purchased from Japan CLEA Inc., Tokyo, Japan. (C3H6BALB)F 1 mice were generated by mating male BALB mice with female C3H mice. To produce (C3H6BALB)F 1 6C3H backcross mice, (C3H6BALB)F 1 females were backcrossed to male C3H mice. All mice were allowed free access to food (CE-2, Japan CLEA Inc., Tokyo, Japan) and water during the entire experiment.
Induction of lung tumors
At 6 weeks of age, each mouse was injected i.p. with urethane (Sigma, St Louis, MO, USA) dissolved in physiological saline at the dose level of 1 mg/g body weight. One hundred and twenty days after this injection, mice were sacri®ced by cervical dislocation and lung tumors were enumerated under a dissecting microscope. For each tumor, diameter was measured with an optical micrometer and recorded. Tumors smaller than 0.1 mm in diameter were not included in the study, because they were often dicult to identify reliably. The spleens of (C3H6BALB)F 1 6C3H backcross mice were collected and frozen as a source from which to extract genomic DNA.
Statistical comparisons of mean tumor multiplicity data were performed using the two-sided Mann-Whitney U test.
Genotypic analysis by PCR
Spleen DNA of each (C3H6BALB)F 1 6C3H backcross mouse was extracted with proteinase K-phenol by a standard method (Lee et al., 1987) and used as the template for PCR genotyping. Since any sex dierence in susceptibility to lung carcinogenesis has been shown to be very small, if present (Malkinson and Beer, 1983; Obata et al., 1996) , we pooled both male and female backcross mice.
For genotyping of the Pas1 gene on distal chromosome 6, the Kras2 gene, which has been shown to be tightly linked to the Pas1 locus (Gariboldi et al., 1993; Devereux et al., 1994; Festing et al., 1994) , was selected. Using the primers FK2i and RK2i, a part of the Kras2 intron 2 polymorphic between BALB and C3H in length was ampli®ed by PCR . In addition, the mice were genotyped by PCR of the D6Mit261 simple sequence repeat (SSR) locus located 35 cM proximal to the Kras2. For the Par2 gene on distal chromosome 18, the PCRbased genotyping was performed at the D18Mit142 SSR locus, which is tightly linked to the Par2 locus (Obata et al., 1996) , and its¯anking SSR loci, D18Mit152 and D18Mit49. All the PCR primer pairs for SSR markers (Dietrich et al., 1996) were purchased from Research Genetics, Huntsville, AL, while the primers for Kras2 was obtained by a custom order according to the published sequences. Non-isotopic PCR conditions used in this study were as previously described (Lee et al., 1995) . The PCR products were run on 7% nondenaturing polyacrylamide gels and stained with ethidium bromide. Under ultraviolet illumination, the PCR products were visualized, photographed and scored for homozygotes and heterozygotes according to strain-speci®c band sizes.
Evaluation of the phenotypic eects of the Pas1 and Par2 genes in (C3H6BALB)F 1 6C3H backcross mice For each marker locus linked to the Pas1 or Par2 loci, the backcross mice were classi®ed into homozygotes and heterozygotes. If a BALB locus exerts a dominant eect on lung tumor multiplicity, the mean tumor multiplicities of these two groups would be expected to be signi®cantly dierent. Statistical evaluation was performed with the two-sided Mann-Whitney U test. Since our aim was to evaluate the phenotypic eects of two speci®c quantitative trait loci, whose chromosomal locations have already been established, the recently proposed criterion of P50.01 for con®rmed' linkage is applicable to declare statistical signi®cance for each locus (Lander and Kruglyak, 1995) . However, to keep the risk of type I errors less than 5% during the whole study, we set our stringent signi®cance threshold as follows (Lander and Kruglyak, 1995) : (1) Since our study evaluated phenotypic eects of two independent loci (i.e. Pas1 and Par2), the P threshold of 0.01 for`con®rmed' linkage was ®rst divided by two; (2) In the study of Par2, we implicitly tested two models (i.e. Pas1-independent and -dependent models). Thus, the value was again divided by two; (3) We investigated the gene eects on three independent phenotypes (i.e. tumor number and size, and Kras2 mutation frequency). Therefore, the value was further divided by three. The ®nal P threshold obtained by this procedure is 0.0008. This setting is conservative, since we tested only one model for the Pas1 locus. LOD score analyses of the quantitative trait loci were also performed using the Mapmaker/QTL program (Lander and Botstein, 1989) . For this purpose, the squareroot value of each tumor multiplicity plus 1 was used in order to improve the ®t of non-normal distributions of tumor multiplicities to a normal one (Snedecor and Cochran, 1989) .
Non-isotopic, PCR-based analysis of activating point mutations in the Kras2 oncogene at codon 61
Most mouse lung tumors induced by urethane have been reported to possess Kras2 oncogenes activated by A to T or G conversions at the second position of codon 61 (You et al., 1989 (You et al., , 1992 Re et al., 1992; Ohmori et al., 1992) . Since such conversions create XbaI or TaqI restriction sites, respectively (George et al., 1985) , we non-isotopically tested for activating point mutations utilizing the restric-tion length polymorphism (Lee and Drinkwater, 1995a and KrasR2 (5'-TTAAACCCACCTATAATGG-3') ( Figure  4) , with lung tumor DNA as the template. The PCR products were then digested with XbaI or TaqI as previously described (Lee and Drinkwater, 1995a) , run on 7% polyacrylamide gels, and stained with ethidium bromide. Under ultraviolet illumination, the RLFPs were observed. Table 3 indicates the expected sizes of bands for the wild type or mutant alleles. There is a native TaqI site slightly upstream of codon 61 (Figure 2) .
A very small percentage of urethane-induced mouse lung tumors were reported to carry an A to T or an A to C conversion at the third position of Kras2 codon 61 (Re et al., 1992; Ohmori et al., 1992) . Since these point mutations create a novel RcaI or MaeIII restriction site, respectively (George et al., 1985) , the PCR products were also analysed for RcaI and MaeIII RFLPs in some cases.
Analysis of ScaI RLFP in intron 3 of Kras2
Manenti et al. recently reported a ScaI RLFP in intron 3 of the mouse Kras2 Figure 2) . They utilized this polymorphism to ®nd the parental bias of the Kras2 codon 61 mutations in urethane-induced lung tumors from (A/J6Mus spretus)F 1 mice, since intron 2 length polymorphism, which has been used for detecting the parental bias for the Kras2 codon 12 mutations, can not be readily applied for codon 61-mutated cases. To detect this polymorphism, a 2.2 kbp sequence of Kras2 including codon 61 of exon 2 and the whole of intron 3 was ampli®ed with KrasF and KrasR (5'-ACCATAGG-CACATCTTCAG-3') primers (Figure 2 ) as described earlier . The PCR products were digested with ScaI restriction enzymes and analysed by electrophoresis on 1.5% agarose gels.
Non-isotopic, PCR-based analysis of activating point mutations in the Kras2 oncogene at codon 12
Several carcinogens other than urethane have been shown to predominantly induce lung tumors with activating point mutations at the ®rst or second position of codon 12 in Kras2 exon 1 . To detect codon 12 mutations, PCR was performed with the primers 12Kras2F (forward primer: 5'-ATAAACTTGTGGTGGT-TGGACCT-3'), which spans between Kras2 codons 4 and 11, and 12Kras2R (reverse primer: 5'-GCAGCGT-TACCTCTATCGTA-3'), which covers the 3' end of exon 1 and the subsequent 5' end of intron 2 (George et al., 1985) . Although sequence of Kras2 codon 11 is known to be GCT (George et al., 1985) , the ®rst base of this codon was arti®cially changed to C in the 12Kras2F primer. Since the wild type sequence of codon 12 is GGT, resultant PCR products 111 bp in length contained a novel MvaI restriction site (i.e. CCTGG) corresponding to codon 11 and subsequent 2 bases of codon 12. Any point mutations at the ®rst or second position of codon 12 abrogate the MvaI site. The mutations were thus detected as resistance of the PCR products to MvaI-digestion.
